...
首页> 外文期刊>Acta Neuropathologica >Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis
【24h】

Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis

机译:缺乏IDH突变可确定WHOⅡ级神经胶质瘤的新型放射学和分子亚型,预后不良

获取原文
获取原文并翻译 | 示例

摘要

The phenotypic heterogeneity of low-grade gliomas (LGGs) is still inconsistently explained by known molecular abnormalities in patients treated according to the present standards of care. IDH1 codon 132 and IDH2 codon 172 sequencing was performed in a series of 47 LGGs and correlated with clinical presentation, MR imaging characteristics, genomic profile and outcome. A total of 38 IDH1 mutations at codon 132 and 2 IDH2 mutations at codon 172 were found, including 35 R132H (87.5%), 2 R132C (5.0%), 1 R132S (2.5%) and 2 R172 M (5%). The IDH mutations were significantly associated with 1p19q deleted genotype (P = 0.031) and p53 expression (P = 0.014). The presence (vs. absence) of IDH mutations was associated with a better outcome (5-year survival rate, 93% vs. 51%, respectively, P = 0.000001). After adjustment for age, tumor location and size, radiologic infiltration pattern and extent of surgery, multivariate analysis confirmed that IDH mutations was an independent favorable prognostic factor (hazard ratio = 40.9; 95% CI, 2.89–578.49, P = 0.006). Furthermore, we showed that patients with IDH-nonmutated tumors were significantly older (P = 0.020) and that these tumors involved significantly more frequently the insula (P = 0.004), were larger in size (>6 cm, P = 0.047), displayed an infiltrative pattern on MRI (P = 0.007) and were all p53 negative with no 1p19q deletion (P < 10−6). The absence of IDH mutations in LGGs identifies a novel entity of LGGs with distinctive location, infiltrative behavior, specific molecular alterations, and dismal outcome. These findings could significantly modify the LGG classification and may represent a new tool to guide patient-tailored therapy.
机译:根据目前的护理标准治疗的患者中,已知的分子异常仍不能一致地解释低度神经胶质瘤(LGG)的表型异质性。 IDH1密码子132和IDH2密码子172测序在一系列47个LGG中进行,并与临床表现,MR成像特征,基因组概况和结果相关。共发现38个IDH1突变在132位密码子和2个IDH2突变在172位密码子,包括35个R132H(87.5%),2个R132C(5.0%),1个R132S(2.5%)和2个R172 M(5%)。 IDH突变与1p19q缺失基因型(P = 0.031)和p53表达(P = 0.014)显着相关。 IDH突变的存在(相对于缺失)与更好的预后相关(5年生存率,分别为93%和51%,P = 0.000001)。在调整年龄,肿瘤位置和大小,放射学浸润模式和手术范围后,多因素分析证实IDH突变是一个独立的有利预后因素(危险比= 40.9; 95%CI,2.89–578.49,P = 0.006)。此外,我们发现IDH未突变的肿瘤患者明显更年长(P = 0.020),并且这些肿瘤累及绝缘岛的频率显着更高(P = 0.004),尺寸更大(> 6 cm,P = 0.047)。 MRI显示为浸润型(P = 0.007),均为p53阴性,无1p19q缺失(P <10 -6 )。 LGG中没有IDH突变,可以鉴定出LGG的新实体,具有独特的位置,浸润行为,特定的分子改变和令人沮丧的结果。这些发现可能会大大改变LGG的分类,并可能代表一种指导患者量身定制的治疗方法的新工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号